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ORIGINAL RESEARCH
Short-term effect of the HMG-CoA reductase 
inhibitor rosuvastatin on erythrocyte nitric oxide 
synthase activity
Abstract: Prevention and treatment of cardiovascular disorders by HMG-CoA reductase 
inhibitors (or statins), beyond their lipid-lowering properties, have been demonstrated 
including activation of the endothelial nitric oxide synthase (eNOS). Beside endothelial cells, 
red blood cells (RBCs) possess NOS and produce nitric oxide (NO), which contributes to 
RBC deformability. The present study tested the capacity of statins to activate NOS in RBCs 
and subsequently to modulate RBC deformability in vitro. Blood samples of healthy young 
volunteers were incubated with or without rosuvastatin. Afterwards RBC-NOS activity and 
RBC deformability were determined. Rosuvastatin incubation signiﬁ  cantly increased NOS 
phosphorylation, NOS dependent NO-formation, and RBC deformability. The NOS inhibitor 
NG- monomethyl-L-arginine reversed the stimulatory effect of rosuvastatin on RBC-NOS 
activity. This NO dependent effect of rosuvastatin might have an important inﬂ  uence on micro-
circulation and may offer new perspectives for the therapeutic use of statins.
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Introduction
Beside endothelial cells, monocytes, cardiomyocytes, and platelets (Förstermann et al 
1998) also red blood cells (RBCs) (Jubelin and Gierman 1996) carry a constitutive 
form of nitric oxide synthase (eNOS). We have recently shown an eNOS-like protein in 
RBC inﬂ  uencing the nitric oxide (NO) production and thereby affecting RBC deform-
ability and platelet aggregation. Apart from its substrate L-arginine, insulin is known 
to activate NOS in RBCs through a phosphatidylinositol-3 kinase (PI3K)-induced 
phosphorylation of the residue serine1177. The substrate conversion rate of L-arginine 
to L-citrulline by RBCs reaches similar levels to that achieved by endothelial cells in 
healthy volunteers, suggesting that RBCs and endothelial cells contribute likewise to 
NO metabolism (Kleinbongard et al 2006). However, since under a variety of diseases 
endothelial cell NOS activity is reduced (“endothelial dysfunction”) (Herman and 
Moncada 2005), RBC-NOS may appear as an interesting pharmacological target to 
increase the total NO-pool and blood rheology.
In clinical trials, statins are beneﬁ  cial in the primary and secondary prevention 
of coronary heart disease. Statins have been shown to possess several pleiotropic 
properties independent of cholesterol lowering in experimental settings.
There are various mechanisms whereby statins may alter NO release. Statins 
regulates the expression of the eNOS and may also increase eNOS activity via post-
translational activation of the PI3K/Akt pathway or through an interaction with the 
molecular chaperone heat-shock protein 90 (Laufs 2003). Statins have been shown 
to increase NO-bioavailability (Schäfer et al 2005) but the source of NO-production 
remains to be assessed. Other studies described effects of statins on the blood rheology 
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including RBC deformability (Szapary et al 2004). Our study 
therefore tested whether or not statins can acutely activate 
RBC-NOS and if so whether this subsequently affects hemor-
heological properties.
Materials and methods
The study was performed in accordance with the rules of 
the internal review board and the tenets of the Helsinki 
protocol.
Sample preparation
For all experiments blood was taken from the antecubital vein 
of healthy volunteers. Measurements of RBC deformability 
and RBC-NOS activity were performed simultaneously 
(n = 8). Phosphorylation of eNOS in RBCs was measured 
immunocytochemically in dependence of rosuvastatin in a 
subset of the mentioned experiments (n = 4).
For measurements of eNOS phosphorylation, NOS 
activity and RBC deformability, the arginase inhibitor 
L-valin (30 mM) and the NOS-substrate L-arginine (3 mM) 
were added to anticoagulated blood samples (Lepirudin 62.5 
μg/ml) which were then incubated for 30 minutes at 37 °C 
with rosuvastatin (20 ng/ml; a concentration achieved in 
human blood during standard therapy [Cooper et al 2003]) or 
buffer as control. In a subset of experiments additionally to 
L-valin and L-arginine the NOS inhibitor NG- monomethyl-
L-arginine (L-NMMA, 300 μM) was added and the blood 
was incubated with or without rosuvastatin (n = 5).
Measurement of eNOS phosphorylation
RBCs incubated with or without rosuvastatin (see above) 
were ﬁ  xed as a blood smear with methanol/paraformaldehyd 
(37%) solution (9:1) and penetrated with PBS/Triton-X-100 
(0.1%). The anti-phospho-eNOS (Ser1177) antibody (1:500, 
rabbit, Upstate, NY) was used as primary antibody; for further 
details see (Kleinbongard et al 2006; Pott et al 2006).
Measurement of nitrite formation as a 
marker of NOS activity
Accumulated plasma nitrite was measured after incubation 
of whole blood using the reductive chemiluminescence tech-
nique (Feelisch et al 2002). Nitrate was quantiﬁ  ed by ﬂ  ow 
injection analysis after speciﬁ  c sample processing with prior 
reduction to nitrite by nitrate reductase (Dejam et al 2003).
Measurement of RBC deformability
The RBC deformability was determined using a modiﬁ  ed 
ﬁ  ltration method (Reid et al 1976). With a negative pressure 
of 0.98 kPa pure RBCs (hematocrit 35% in buffer) were 
sucked through a 5 μm pore ﬁ  lter and the ﬂ  ow rate (ml/min) 
was measured.
Statistical analysis
Data are expressed as mean ± SEM. Two-tailed paired 
Students t test was used to analyze nitrite, nitrate, and 
eNOS-phosphorylation data, while the Wilcoxon test was 
used to compare RBC deformability. For multiple com-
parisons one-way ANOVA and Bonferoni test were applied. 
p-values 0.05 were accepted as signiﬁ  cant.
Results
RBC-NOS activity is increased 
by rosuvastatin
A signiﬁ  cantly increased phosphorylation of RBC-NOS after 
incubation with rosuvastatin from 3.76 ± 2.98 arbitrary units 
(au) to 24.88 ± 4.35 au (p < 0.02) was detected (Figure 1A). 
The oxidative metabolite of NO, nitrite, has been shown 
to reﬂ  ect changes of NOS activity in vivo and in vitro 
(Kleinbongard et al 2003, 2006). A nitrite accumulation in 
plasma after incubation of whole blood with rosuvastatin 
from 55.8 ± 7.9 nmol/l to 98.2 ± 12.4 nmol/l (p < 0.05, 
Figure1B) was detectable. Plasma nitrate levels remained 
unchanged. The specific NOS-inhibitor L-NMMA in 
addition to rosuvastatin decreased plasma nitrite levels from 
64.3 ± 4.5 nmol/l to 46.6 ± 4.0 nmol/l (p < 0.01); incubation 
with L-NMMA alone decreased plasma nitrite levels to 
43.9 ± 2.0 nmol/l (p < 0.01 to control, no signiﬁ  cance to 
inhibition with rosuvastatin).
Increased RBC deformability and RBC 
NO-production caused by rosuvastatin
RBC deformability increased signiﬁ  cantly after incubation 
with rosuvastatin from 1.96 ± 0.34 ml/min (controls) to 
2.63 ± 0.31 ml/min (p < 0.036). Plasma nitrite levels 
correlated to RBC deformability (R = 0.59, p < 0.0001; 
Figure 2).
Discussion
The existence of a NO-synthesis in RBC and the fact that it 
can be modulated raises new perspectives on treatment of 
vascular diseases. Until now nothing is known about eNOS 
stimulating therapeutical agents and RBC-NOS activity 
or function. The novel ﬁ  nding of this study is that statin 
increases RBC-NOS activity which subjects to an improved 
RBC deformability.Vascular Health and Risk Management 2007:3(6) 1071
Increased RBC-NOS activity by statins
In endothelial cells statins cause PI3K stimulation 
recruiting a number of signalling molecules to the mem-
brane, including PI3 dependent kinase. This kinase activates 
Akt which further phosphorylates eNOS leading to Ca2+ 
independent enzyme activation (Endres and Laufs 2004). 
In this study, a signiﬁ  cantly increased phosphorylation 
of RBC-NOS after incubation with rosuvastatin could be 
shown (Figure 1A). Phoshorylation at Ser1177 of RBC-
NOS could also been induced by insulin, which is a known 
activator of the PI3K pathway (Kleinbongard et al 2006). 
After incubation of whole blood for a period of 30 minutes, 
plasma nitrite has been shown to reﬂ  ect RBC-NOS activity 
in vitro (Kleinbongard et al 2006). Here we could show a 
parallel rosuvastatin-dependent increase of plasma nitrite 
as a marker for RBC-NOS activity, and RBC-NOS phos-
phorylation (Figure1B). Rosuvastatin-dependent RBC-NOS 
activation could be impeded using a speciﬁ  c NOS-inhibitor. 
Our data, however, imply that RBC-NOS could be regulated 
through a similar pathway as shown in endothelial cells, 
since rosuvastatin caused a signiﬁ  cant increase in RBC-NOS 
phosphorylation and NO production. Unknown are the 
potential upstream pathways of such phosphorylation in 
RBCs. Described increase of eNOS expression or mRNA 
stabilization by statins could be excluded in the anucleated 
RBC. Possible regulatory mechanisms are modiﬁ  cation of 
eNOS interacting proteins like heat shock protein 90 or 
various protein kinases (Noma et al 2006). Protein kinase B 
in RBC precursors (Kadri et al 2005) and RBC membrane 
proteins (α−spectrin and β-spectrin) with more than 50% 
similarities to the heat shock protein 90 (Bhattacharyya et al 
2004) have been identiﬁ  ed. Statins may also block proteins 
interfering with calcium/calmodulin by sequestering eNOS 
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Figure 1 Rosuvastatin increases RBC-NOS activity. RBC-NOS activity was measured by the level of eNOS protein phosphorylation and by accumulated plasma nitrite 
depending on rosuvastatin. (A) Phosphorylation of eNOS at Ser1177 was used to examine the phosphorylation dependent activation status of the eNOS. RBCs incubated 
with rosuvastatin showed a signiﬁ  cant rise of eNOS phosphorylated at Ser1177 as compared with control. (B) Accumulated nitrite was determined in blood samples after 
incubation under control conditions with and without rosuvastatin. Changes in plasma nitrite reﬂ  ect the sum of the release (due to NOS-dependent NO-formation) and 
the reuptake of nitrite by RBC.
Note: *indicates signiﬁ  cant differences from control.Vascular Health and Risk Management 2007:3(6) 1072
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Figure 2 Effect of rosuvastatin on RBC-NOS activity and RBC deformability. Parallel to the RBC-NOS activity (detected as accumulated plasma nitrite concentration) ﬂ  ow 
rate of RBC through a microﬁ  lter (as a measure of RBC deformability) were determined after incubation of whole blood with (black squares) and without rosuvastatin 
(white squares).
into caveolae (Pelat et al 2003). Calmodulin is present in 
RBC (Jubelin and Gierman 1996), and RBC NOS activity 
is calcium-dependent (Kleinbongard et al 2006). Therefore, 
some of the well known NOS regulatory mechanisms can 
be inﬂ  uenced by rosuvastatin and are feasible in regulation 
of RBC-NOS activity.
Vasodilation and particularly RBC deformability 
(Mchedlishvili and Maeda 2001) are basic needs of 
microcirculatory blood ﬂ  ow. Reduction of RBC deformability 
and microcirculatory blood ﬂ  ow has been described during 
several pathophysiological circumstances such as arterial 
hypertension (Cicco and Pirrelli 1999) and diabetes mellitus 
(Symeonidis et al 2001). Statin therapy has been shown to 
inﬂ  uence RBC deformability after long-term treatment par-
ticularly in hypercholesterolemic patients which is thought 
to relate to a decrease of cholesterol in the erythrocyte lipid 
double layer (Kohno et al 1997). Up to now this improvement 
of statin-dependent change in RBC deformability was related 
to the change in the RBC membrane lipid composition. 
Here we see an effect of rosuvastatin treatment on RBC 
deformability and RBC-NOS activity (Figure 2). These data 
suggest an alternative explanation relating the increased 
deformability following statin treatment to the increase in 
RBC-NOS activity. In nearly all blood cells, namely platelets, 
monocytes, lymphocytes (Förstermann et al 1998) and RBCs 
(Kleinbongard et al 2006) a constitutive form of NOS has 
been demonstrated. Neutrophils have been shown to inhibit 
platelet aggregation after NOS stimulation. Interestingly, the 
effect was more pronounced after whole blood incubation 
as compared with incubation with platelets itself or a 
combination of platelets and neutrophils (De La Cruz et al 
1999). Cell-cell interaction with erythrocytes was suggested 
as possible explanation for this result and, indeed, our data 
support such hypothesis.Vascular Health and Risk Management 2007:3(6) 1073
Increased RBC-NOS activity by statins
Emerging evidence indicates that the microcirculation 
is a crucial target for the pleiotropic actions of statins. 
The major pharmacodynamic actions of statins currently 
invoked to explain their vascular protective effects are 
increased blood ﬂ  ow and attenuated inﬂ  ammatory events 
in the vessel wall. Effects of statins influencing the 
microcirculation are anti-adhesive actions by inhibiting 
leukocyte-endothelium interactions or the effects of cell 
proliferation an angiogenesis. These effects are related to 
important functions of the microcirculation under normal 
conditions and in disease states. In particular, increased 
bioavailability of NO in the microcirculation by statins 
could prevent pathophysiological cell-cell interactions and 
may reduce oxidative stress at the vessel wall. RBC-NOS 
might appear as an interesting pharmacological target to 
increase the total NO-pool. Amelioration of blood ﬂ  ow 
and increased delivery of oxygen and nutrients should be 
beneﬁ  cial in pathologically changed circulation for example 
after myocardial or cerebral ischemia.
Taken together all these ﬁ  ndings are of clinical interest 
because they may uncover new mechanisms of the beneﬁ  cial 
action of statins in cardiovascular disease. In vivo experi-
ments are necessary to identify the potential of RBC-NOS 
in patients with NO deﬁ  ciency and to develop new strategies 
to enhance expression and activity of RBC-NOS.
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